Skip to main content
Erschienen in: International Urogynecology Journal 7/2008

01.07.2008 | Original Article

A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis

verfasst von: M. Cervigni, F. Natale, L. Nasta, A. Padoa, R. Lo Voi, D. Porru

Erschienen in: International Urogynecology Journal | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

The aims of this study were to evaluate the efficacy and tolerability of intravesical instillations of high-molecular-weight hyaluronic acid (HA) 1.6% and chondroitin sulfate (CS) 2.0% in patients with refractory painful bladder syndrome/interstitial cystitis (PBS/IC) and to observe their impact on Quality of Life. Twenty-three women were enrolled. They received bladder instillations with HA and CS weekly for 20 weeks and then monthly for 3 months. Mean follow-up after completion of therapy was 5 months. We observed a significant improvement in urinary symptoms on voiding diaries and Visual Analogue Scale for frequency (p = 0.045), urgency (p = 0.005), and pain (p = 0.001). The O’Leary–Sant Interstitial Cystitis Symptom Index and Interstitial Cystitis Problem Index resulted in a significant improvement in both scores (p = 0.004 and 0.01, respectively). The Pelvic Pain and Urgency/Frequency Symptom Scale only showed significant improvement in the symptom score (p = 0.001). This promising experience seems to offer an additional therapeutic option in patients with refractory PBS/IC.
Literatur
1.
Zurück zum Zitat Tait J (1994) Urethral syndrome (a bacterial cystitis) search for a pathogen. Br J Urol 57:552–556 Tait J (1994) Urethral syndrome (a bacterial cystitis) search for a pathogen. Br J Urol 57:552–556
2.
Zurück zum Zitat Ochs RL et al (1994) Autoantibodies in interstitial cystitis. J Urol 151:587–592PubMed Ochs RL et al (1994) Autoantibodies in interstitial cystitis. J Urol 151:587–592PubMed
3.
Zurück zum Zitat Pang X (1995) Increased number of substance P positive nerve fibres in interstitial cystitis. Br J Urol 75:744–750PubMed Pang X (1995) Increased number of substance P positive nerve fibres in interstitial cystitis. Br J Urol 75:744–750PubMed
4.
Zurück zum Zitat McGillis JP (1990) Immunomudulation by tachykinin neuropeptides. Ann N Y Acad Sci 594:85–94PubMedCrossRef McGillis JP (1990) Immunomudulation by tachykinin neuropeptides. Ann N Y Acad Sci 594:85–94PubMedCrossRef
5.
Zurück zum Zitat Rosamilia A (1999) Activation of the kallikrein kinin system in interstitial cystitis. J Urol 162:129–134PubMedCrossRef Rosamilia A (1999) Activation of the kallikrein kinin system in interstitial cystitis. J Urol 162:129–134PubMedCrossRef
6.
Zurück zum Zitat McMahon SB (1996) NGF as a mediator of inflammatory pain. Philos Trans R Soc Lond B Biol Sci 351:431–440PubMedCrossRef McMahon SB (1996) NGF as a mediator of inflammatory pain. Philos Trans R Soc Lond B Biol Sci 351:431–440PubMedCrossRef
7.
Zurück zum Zitat Niku SD (1994) A new method for cytodestruction of bladder epithelium using protamine sulphate and urea. J Urol 152:1025–1028PubMed Niku SD (1994) A new method for cytodestruction of bladder epithelium using protamine sulphate and urea. J Urol 152:1025–1028PubMed
8.
Zurück zum Zitat Wesselmann U (1997) Mechanism of referred visceral pain: uterine inflammation in the adult virgin rat results in neurogenic plasma extravasation in the skin. Pain 73:309–317PubMedCrossRef Wesselmann U (1997) Mechanism of referred visceral pain: uterine inflammation in the adult virgin rat results in neurogenic plasma extravasation in the skin. Pain 73:309–317PubMedCrossRef
9.
Zurück zum Zitat Theodarides TC, Sant GR (2005) A pilot label study of Cystoprotek in interstitial cystitis. Int J Immunopathol Pharmacol 18(1):183–188 Theodarides TC, Sant GR (2005) A pilot label study of Cystoprotek in interstitial cystitis. Int J Immunopathol Pharmacol 18(1):183–188
10.
Zurück zum Zitat Morales A, Emerson L, Nickel JC (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156:45–48PubMedCrossRef Morales A, Emerson L, Nickel JC (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156:45–48PubMedCrossRef
11.
Zurück zum Zitat Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM, Usai E (1997) Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 59(1):26–29PubMedCrossRef Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM, Usai E (1997) Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 59(1):26–29PubMedCrossRef
12.
Zurück zum Zitat Kallenstrup EB, Joregensen S, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol 39:143–147CrossRef Kallenstrup EB, Joregensen S, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol 39:143–147CrossRef
13.
Zurück zum Zitat Gillenwater JY, Wein AJ (1988) Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol 140(1):203–206PubMed Gillenwater JY, Wein AJ (1988) Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol 140(1):203–206PubMed
14.
15.
Zurück zum Zitat Lubeck DP, Witmore K, Sant GR, Alvares-Horine S, Lai C (2001) Psycometric validation of the O’Leary–Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology 57:62–66PubMedCrossRef Lubeck DP, Witmore K, Sant GR, Alvares-Horine S, Lai C (2001) Psycometric validation of the O’Leary–Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology 57:62–66PubMedCrossRef
16.
Zurück zum Zitat Ito T, Tomoe H, Ueda T, Yoshimura N, Sant G, Hanno P (2003) Clinical symptoms scale for interstitial cystitis for diagnosis and for following the course of the disease. Int J Urol 10:S24PubMedCrossRef Ito T, Tomoe H, Ueda T, Yoshimura N, Sant G, Hanno P (2003) Clinical symptoms scale for interstitial cystitis for diagnosis and for following the course of the disease. Int J Urol 10:S24PubMedCrossRef
17.
Zurück zum Zitat Evans RJ, Sant GR (2007) Current diagnosis of interstitial cystitis an evolving paradigm. Urology 69(Suppl 4):64–72PubMedCrossRef Evans RJ, Sant GR (2007) Current diagnosis of interstitial cystitis an evolving paradigm. Urology 69(Suppl 4):64–72PubMedCrossRef
18.
Zurück zum Zitat Toft BR, Nordling J (2006) Recent developments of intravesical therapy of painful bladder sindrome/interstitial cystitis: a review. Curr Opin Urol 16(4):268–272PubMedCrossRef Toft BR, Nordling J (2006) Recent developments of intravesical therapy of painful bladder sindrome/interstitial cystitis: a review. Curr Opin Urol 16(4):268–272PubMedCrossRef
19.
Zurück zum Zitat Kho HC (2005) Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 75(2):170–174CrossRef Kho HC (2005) Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 75(2):170–174CrossRef
20.
Zurück zum Zitat Parsons CL, Housely T, Schmidt JD et al (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73:504–7PubMedCrossRef Parsons CL, Housely T, Schmidt JD et al (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73:504–7PubMedCrossRef
21.
Zurück zum Zitat Parsons CL (2005) Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 65(1):45–48PubMedCrossRef Parsons CL (2005) Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 65(1):45–48PubMedCrossRef
22.
Zurück zum Zitat Leppilahti M, Hellstrom P, Tammela TL (2002) Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 60(1):46–51PubMedCrossRef Leppilahti M, Hellstrom P, Tammela TL (2002) Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 60(1):46–51PubMedCrossRef
23.
Zurück zum Zitat Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47:393–397PubMedCrossRef Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47:393–397PubMedCrossRef
24.
Zurück zum Zitat Ahmad I, Sarath Krishna N, Meddings RM (2008) Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory interstitial cystitis: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct Sep 14 (in press) Ahmad I, Sarath Krishna N, Meddings RM (2008) Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory interstitial cystitis: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct Sep 14 (in press)
Metadaten
Titel
A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis
verfasst von
M. Cervigni
F. Natale
L. Nasta
A. Padoa
R. Lo Voi
D. Porru
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 7/2008
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-008-0572-4

Weitere Artikel der Ausgabe 7/2008

International Urogynecology Journal 7/2008 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.